Atherosclerotic Cardiovascular Disease Risk and Lipid-Lowering Therapy Requirement in China.

ABSTRACT:

Background

Lipid-lowering therapy (LLT) is one of the key strategies for reducing the atherosclerotic cardiovascular disease (ASCVD) burden. However, little is known about the percentage of people in need of different LLT regimens to achieve optimal targets of low-density lipoprotein cholesterol (LDL-C), and the corresponding cost and benefit.

Methods

We conducted a simulation study based on the data from the nationwide China PEACE MPP population cohort (2015-2020), from which we included 2,904,914 participants aged 35-75 years from all the 31 provinces in mainland China. Participants were grouped based on their 10-year ASCVD risks, then entered into a Monte Carlo model which was used to perform LLT intensification simulation scenarios to achieve corresponding LDL-C goals in

SUBMITTER: Bi L 

PROVIDER: S-EPMC8996051 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature